Sepsis and Septic Shock
11
3
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (11)
Adjunctive Fludrocortisone in Septic Shock
Written Sepsis Education for Patients
Hemodynamic Venous Congestion Ultrasound (VExUS) by ICU Nurses in Sepsis Patients.
Role of Transposable Elements in Septic Immune Aging
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections
Study on the Construction and Application of Early Warning Model of Sepsis in Critically Ill Patients
Fibrinolysis Resistance in Infection and Trauma
Proteinuria During Sepsis and Septic Shock: Characterization and Association With ARDS
The Prognostic Impact of Right Ventricular Systolic Dysfunction on the Survival of Patients With Sepsis and Septic Shock
Circulating Free Hemoglobin and Microcirculation After Administration of Paracetamol in Febrile Septic Patient